Business
Novavax Reports Second Quarter 2020 Financial and Operational Results
Announced Positive Phase 1 data of Phase 1/2 clinical trial of NVX-CoV2373Secured $2 billion in funding for global coronavirus vaccine program through CEPI,
About this update from Novavax, Inc.
[{"type":"text","content":"Announced Positive Phase 1 data of Phase 1/2 clinical trial of NVX-CoV2373Secured $2 billion in funding for global coronavirus vaccine program through CEPI, DoD, and OWSExpanded large scale global manufacturing capacity through acquisition and partneringCompany to host conference call today at 4:30 p.m. ET GAITHERSBURG, Md., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced its financial results and operational highlights for the second quarter ended June 30, 2020.\n “Novavax’ unprecedented development activities for NVX-CoV2373 and progress continued through the second quarter,” said Stanley C. Erck, President and Chief Executive Officer of Novavax. “Since identifying a candidate vaccine to address the COVID-19 pandemic in March, we’ve secured significant funding, implemented global manufacturing capacity and completed and reported our successful Phase 1 trial. We’ve also expanded our senior leadership team to advance our efforts to bring NVX-CoV2373 to market as rapidly as possible and grow our infrastructure to support commercial stage operations.” Second Quarter 2020 and Recent Highlights COVID-19 Program Announced Phase 1 data from its Phase 1/2 randomized, observer-blinded, placebo-controlled clinical trial of NVX-CoV2373 in healthy adults 18-59 years of age-- Neutralization levels numerically superior to convalescent serum-- Significantly higher immune response with 2-dose, Matrix-MTM adjuvanted vaccine-- Strong T cell responses-- Reassuringly safe and tolerable vaccine profile-- Presentation included on Novavax website here-- Data submitted for peer-review publication and posted to online preprint server at medRxiv.org Demonstrated protection and high immunogenicity in animal models-- Presented data from non-human primate models that demonstrate protection in challenge studies, enhancement of multifunctional T cells, and production of anti-S IgG and neutralizing antibodies-- Data submitted for peer-review publication and posted to online preprint server at medRxiv.org Secured $2 billion in funding for development and commercialization of NVX-CoV2373-- Coalition for Epidemic Preparedness Innovations (CEPI) funding up to $388 million-- U.S. Department of Defense (DoD) funding up to $60 milli...